| Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure–activity relationship studies S Gemma, L Savini, M Altarelli, P Tripaldi, L Chiasserini, SS Coccone, ... Bioorganic & Medicinal Chemistry 17 (16), 6063-6072, 2009 | 78 | 2009 |
| Mimicking the intramolecular hydrogen bond: synthesis, biological evaluation, and molecular modeling of benzoxazines and quinazolines as potential antimalarial agents S Gemma, C Camodeca, M Brindisi, S Brogi, G Kukreja, S Kunjir, ... Journal of medicinal chemistry 55 (23), 10387-10404, 2012 | 71 | 2012 |
| N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity E Nuti, AR Cantelmo, C Gallo, A Bruno, B Bassani, C Camodeca, ... Journal of Medicinal Chemistry 58 (18), 7224-7240, 2015 | 67 | 2015 |
| Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: Further structure–activity relationships, in vivo studies, and preliminary toxicity profiling S Gemma, C Camodeca, S Sanna Coccone, BP Joshi, M Bernetti, ... Journal of medicinal chemistry 55 (15), 6948-6967, 2012 | 51 | 2012 |
| Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models C Camodeca, E Nuti, L Tepshi, S Boero, T Tuccinardi, EA Stura, A Poggi, ... European Journal of Medicinal Chemistry 111, 193-201, 2016 | 50 | 2016 |
| ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing MR Zocchi, C Camodeca, E Nuti, A Rossello, R Venè, F Tosetti, I Dapino, ... Oncoimmunology 5 (5), e1123367, 2016 | 49 | 2016 |
| Sugar‐Based Arylsulfonamide Carboxylates as Selective and Water‐Soluble Matrix Metalloproteinase‐12 Inhibitors E Nuti, D Cuffaro, F D'Andrea, L Rosalia, L Tepshi, M Fabbi, G Carbotti, ... ChemMedChem 11 (15), 1626-1637, 2016 | 41 | 2016 |
| Development of thioaryl-based matrix metalloproteinase-12 inhibitors with alternative zinc-binding groups: Synthesis, potentiometric, NMR, and crystallographic studies E Nuti, D Cuffaro, E Bernardini, C Camodeca, L Panelli, S Chaves, ... Journal of Medicinal Chemistry 61 (10), 4421-4435, 2018 | 40 | 2018 |
| Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells F Tosetti, R Venè, C Camodeca, E Nuti, A Rossello, C D'Arrigo, D Galante, ... Oncoimmunology 7 (5), e1421889, 2018 | 38 | 2018 |
| Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues E Nuti, B Bassani, C Camodeca, L Rosalia, AR Cantelmo, C Gallo, D Baci, ... European journal of medicinal chemistry 138, 890-899, 2017 | 37 | 2017 |
| Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models E Nuti, F Casalini, S Santamaria, M Fabbi, G Carbotti, S Ferrini, L Marinelli, ... Journal of medicinal chemistry 56 (20), 8089-8103, 2013 | 27 | 2013 |
| ADAM metalloproteinases as potential drug targets C Camodeca, D Cuffaro, E Nuti, A Rossello Current Medicinal Chemistry 26 (15), 2661-2689, 2019 | 26 | 2019 |
| Resveratrol-like compounds as SIRT1 activators L Ciccone, E Piragine, S Brogi, C Camodeca, R Fucci, V Calderone, ... International Journal of Molecular Sciences 23 (23), 15105, 2022 | 23 | 2022 |
| Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors S Sjøli, E Nuti, C Camodeca, I Bilto, A Rossello, JO Winberg, I Sylte, ... European Journal of Medicinal Chemistry 108, 141-153, 2016 | 19 | 2016 |
| MMP‐8 Is Critical for Dexamethasone Therapy in Alkali‐Burned Corneas Under Dry Eye Conditions F Bian, C Wang, J Tukler‐Henriksson, SC Pflugfelder, C Camodeca, ... Journal of cellular physiology 231 (11), 2506-2516, 2016 | 18 | 2016 |
| Matrix metalloproteinase-12 inhibitors: synthesis, structure-activity relationships and intestinal absorption of novel sugar-based biphenylsulfonamide carboxylates D Cuffaro, C Camodeca, F D'Andrea, E Piragine, L Testai, V Calderone, ... Bioorganic & Medicinal Chemistry 26 (22), 5804-5815, 2018 | 16 | 2018 |
| Bifunctional inhibitors as a new tool to reduce cancer cell invasion by impairing MMP-9 homodimerization E Nuti, L Rosalia, D Cuffaro, C Camodeca, C Giacomelli, E Da Pozzo, ... ACS Medicinal Chemistry Letters 8 (3), 293-298, 2017 | 16 | 2017 |
| Bivalent inhibitor with selectivity for trimeric MMP-9 amplifies neutrophil chemotaxis and enables functional studies on MMP-9 proteoforms E Nuti, A Rossello, D Cuffaro, C Camodeca, J Van Bael, D van der Maat, ... Cells 9 (7), 1634, 2020 | 15 | 2020 |
| Focus on human monoamine transporter selectivity. New human DAT and NET models, experimental validation, and SERT affinity exploration G Ortore, E Orlandini, L Betti, G Giannaccini, MR Mazzoni, C Camodeca, ... ACS Chemical Neuroscience 11 (20), 3214-3232, 2020 | 13 | 2020 |
| Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP) D Cuffaro, E Nuti, V Gifford, N Ito, C Camodeca, T Tuccinardi, S Nencetti, ... Bioorganic & Medicinal Chemistry 27 (1), 196-207, 2019 | 12 | 2019 |
